Fibroblast Invasive Migration into Fibronectin/fibrin Gels Requires a Previously Uncharacterized Dermatan Sulfate-CD44 Proteoglycan
Overview
Affiliations
After tissue injury, fibroblast migration from the peri-wound collagenous stroma into the fibrin-laden wound is critical for granulation tissue formation and subsequent healing. Recently we found that fibroblast transmigration from a collagen matrix into a fibrin matrix required the presence of fibronectin. Several integrins-alpha 4 beta 1, alpha 5 beta 1, and alpha v beta 3-with known fibronectin binding affinity were necessary for this invasive migration. Here we examined another family of cell surface receptors: the proteoglycans. We found that dermatan sulfate was required for fibroblast migration into a fibronectin/fibrin gel. This conclusion was based on beta-xyloside inhibition of glycanation and specific glycosaminoglycan degradation. CD44, a cell surface receptor known to bind hyaluronan, not infrequently exists as a proteoglycan, decorated with various glycosaminoglycan chains including heparan sulfate and chondroitin sulfate, and as such can bind fibronectin. We found that CD44H, the non-spliced isoform of CD44, was necessary for fibroblast invasion into fibronectin/fibrin gels. Resting fibroblasts expressed mostly nonglycanated CD44H core protein, which became glycanated with chondroitin sulfate and dermatan sulfate, but not heparan sulfate, after a 24 h incubation with platelet-derived growth factor, the stimulus used in the migration assay. These results demonstrate that dermatan sulfate-CD44H proteoglycan is essential for fibroblast migration into fibrin clots and that platelet-derived growth factor, the stimulus for migration, induces the production of chondroitin-sulfate- and dermatan-sulfate-glycanated CD44H.
Fibrin gel enhanced trilayer structure in cell-cultured constructs.
Snyder Y, Jana S Biotechnol Bioeng. 2023; 120(6):1678-1693.
PMID: 36891782 PMC: 10182258. DOI: 10.1002/bit.28371.
Role of hyaluronic acid in periodontal therapy (Review).
Bhati A, Fageeh H, Ibraheem W, Fageeh H, Chopra H, Panda S Biomed Rep. 2022; 17(5):91.
PMID: 36278244 PMC: 9535241. DOI: 10.3892/br.2022.1574.
CD44 Glycosylation as a Therapeutic Target in Oncology.
Liao C, Wang Q, An J, Chen J, Li X, Long Q Front Oncol. 2022; 12:883831.
PMID: 35936713 PMC: 9351704. DOI: 10.3389/fonc.2022.883831.
Wang J, Zhang W, Roehrl V, Roehrl M, Roehrl M Front Immunol. 2022; 13:831849.
PMID: 35401574 PMC: 8987778. DOI: 10.3389/fimmu.2022.831849.
3D in vitro M2 macrophage model to mimic modulation of tissue repair.
Sapudom J, Karaman S, Mohamed W, Garcia-Sabate A, Quartey B, Teo J NPJ Regen Med. 2021; 6(1):83.
PMID: 34848722 PMC: 8633361. DOI: 10.1038/s41536-021-00193-5.